Kollagenosen

Schlüsselwörter

systemische Sklerose - Dermatomyositis - Lupus erythematodes - Sjögren-Syndrom

Keywords

systemic sclerosis - dermatomyositis - lupus erythematosus - Sjögren’s syndrome

• Literatur

• 1 Alchi B, Jayne D, Labopin M et al. Autologous haematopoietic stem cell transplantation for systemic lupus erythematodes. Lupus 2013; 22: 245-253
• 2 Alemo Munters L, Dastmalchi M, Katz A et al. Improved exercise performance and increased aerobic capacity after endurance training of patients with stable polymyositis and dermatomyositis. Arthritis Res Ther 2013; 15: R83
• 3 Dooley MA, Houssiau F, Aranow C et al. Effect on belimumab treatment on renal outcomes: results from the phase 3 belimumab clinical trials in patients with SLE. Lupus 2013; 22: 63-72
• 4 Oddis CV, Reed AM, Aggarwal R et al. Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis. Arthritis Rheum 2013; 65: 314-324
• 5 Panopoulos ST, Bournia VK et al. Mycophenolat versus cyclophosphamide for progressive interstitial lung disease associated with systemic sclerosis. Lung 2013; 191: 483-489
• 6 Pego-Reigosa JM, Cobo-Ibáñez T, Calvo-Alén J et al. Efficacy and safety of non-biologic immunsuppressants in the treatment of non-renal systemic lupus erythematodes. Arthritis Car Res 2013; Epub ahead of print
• 7 Petri M, Wallace DJ, Spindler A et al. Sifalimumab, a human anti-inferferon-α monoclonal antibody, in systemic lupus erythematodes. Arthritis Rheum 2013; 65: 1011-1021
• 8 Ramos-Casals M, Brito-Zerón P et al. Systemic involvement in primary Sjögren’s syndrome evaluated by the EULAR-SS disease activity index. Rheumatology 2014; 53: 321-331
• 9 Smith V, Piette Y, van Praet JT et al. Two-year results of an open pilot study of a 2-treatment course with rituximab in patients with early systemic sclerosis with diffuse skin involvement. J Rheumatol 2013; 40: 52-57
• 10 Turiel M, Gianturco L, Ricci C et al. Silent cardiovascular involvement in patients with diffuse systemic sclerosis. Arthr Care Res 2013; 65: 274-280
• 11 Wallace DJ, Kalunian K et al. Efficacy and safety of epratuzumab in patients with moderate / severe active systemic lupus erythematodes. Ann Rheum Dis 2014; 73: 183-190
• 12 Witt M, Grunke M, Proft F et al. Clinical outcomes and safety of rituximab treatment for patients with systemic lupus erythematodes (SLE) – results from a nationwide cohort in Germany (GRAID). Lupus 2013; 22: 1142-1149
• 13 Yahya F, Jasmin R, Ng CT et al. Open label randomized controlled trial assessing the efficacy of mycophenolate sodium against other conventional immunosuppressive agents in active systemic lupus erythematodes patients without renal involvement. Int J Rheum Dis 2013; 16: 724-730